Publication date
2015-08Author
Chan, K.K.Matchett, K.B.
McEnhill, P.M.
Dakir, El-Habib
McMullin, M.F.
El-Tanani, Y.
Patterson, Laurence H.
Faheem, A.
Rudland, P.S.
McCarron, P.A.
El-Tanani, Mohamed
Peer-Reviewed
YesOpen Access status
closedAccessAccepted for publication
20/05/2015
Metadata
Show full item recordAbstract
Breast cancer is one of the most prevalent malignancies worldwide. It consists of a group of tumor cells that have the ability to grow uncontrollably, overcome replicative senescence (tumor progression) and metastasize within the body. Metastases are processes that consist of an array of complex gene dysregulation events. Although these processes are still not fully understood, the dysregulation of a number of key proteins must take place if the tumor cells are to disseminate and metastasize. It is now widely accepted that future effective and innovative treatments of cancer metastasis will have to encompass all the major components of malignant transformation. For this reason, much research is now being carried out into the mechanisms that govern the malignant transformation processes. Recent research has identified key genes involved in the development of metastases, as well as their mechanisms of action. A detailed understanding of the encoded proteins and their interrelationship generates the possibility of developing novel therapeutic approaches. This review will focus on a select group of proteins, often deregulated in breast cancer metastasis, which have shown therapeutic promise, notably, EMT, E-cadherin, Osteopontin, PEA3, Transforming Growth Factor Beta (TGF-β) and Ran.Version
No full-text in the repositoryCitation
Chan KK, Matchett KB, McEnhill PM et al (2015) Protein deregulation associated with breast cancer metastasis. Cytokine and Growth Factor Reviews. 26(4): 415-423.Link to Version of Record
https://doi.org/10.1016/j.cytogfr.2015.05.002Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.1016/j.cytogfr.2015.05.002